OX40 ligand expressed by DCs costimulates NKT and CD4⁺ Th cell antitumor immunity in mice
J. Clin. Invest. Jamal Zaini, et al. 117:3330 doi:10.1172/JCI32693 [Go to this article.]

Figure 2
Tumor-bearing mice treated with intratumoral administration of AdOX40L-modified DCs. (A) Tumor growth. B16-F10 tumor–bearing mice were treated by intratumoral injection of DCs modified with AdOX40L (circles) or AdNull (triangles). Tumor-bearing mice without any treatment (squares) were used as controls. (B) Tumor-specific cytotoxic T cell response. Ten days after the treatment described in A, splenocytes were isolated and then assayed for cytolytic function by using B16-F10 or LLC cells as target cells. (C) Immunohistochemical evaluation of tumors’ CD4⁺ and CD8⁺ cells. Three days after the treatment described in A, the tumors were dissected, and the frozen tumor sections were stained with anti-CD4 or anti-CD8 antibodies. Numbers at bottom right of each panel denote the number of positive cells per 10 random high-power fields (original magnification, ×400). (D) Role of CD4⁺ and CD8⁺ T cells in tumor growth. The study was similar to that in A, but CD4⁺ T cell^–/– (circles), CD8⁺ T cell^–/– (triangles) or wild-type mice (blue squares) bearing B16-F10 tumors were treated with AdOX40L-modified DCs. (E) Role of CD4⁺ and CD8⁺ T cells in tumor-specific cytotoxic T cell response. Ten days after the treatment as in D, splenocytes were isolated and assayed for cytolytic function. (F) Role of OX40 on CD4⁺ T cells and in tumor growth. The study was similar to that in D, but the CD4⁺ T cell^–/– mice were reconstituted with OX40^–/– (circles) or wild-type CD4⁺ T cells (triangles) 1 day before the treatment.